Intellia Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 14, 2025 Deadline to file Lead Plaintiff Motion

Core Viewpoint - Intellia Therapeutics, Inc. is facing a class action lawsuit from investors who purchased securities during a specified period, alleging misleading statements regarding the viability of its drug development programs [1][4]. Company Overview - Intellia is a genome editing company focused on developing curative therapeutics, with a notable project being NTLA-3001 for treating alpha-1 antitrypsin deficiency-associated lung disease [3]. Allegations in the Lawsuit - The lawsuit claims that Intellia's management made false or misleading statements about the viability and development of NTLA-3001, including: - Misrepresentation of reliable information regarding NTLA-3001's development and marketing potential [4]. - Overly optimistic timelines for dosing and future studies that did not align with reality [4]. - Lack of capability to timely dose patients or maintain research and development for NTLA-3001 due to the challenges of viral-based editing methods [4]. - Concerns about the cost and inefficiency of viral-based editing drugs, even if NTLA-3001 was successful [4]. Impact of Company Reorganization - On January 9, 2025, Intellia announced a reorganization, prioritizing resources towards NTLA-2002 and nex-z, leading to the discontinuation of NTLA-3001. This announcement resulted in a stock price drop of over 15% [5].